Use of Faricimab in the real-world clinical practice for non-treatment naive neovascular age-related macular degeneration patients

被引：0
|
作者：
Tran, Donald [1 ]
Trung M. Dang [1 ]
Moodie, Jonathan [1 ]
Luckie, Alan [1 ]
机构：
[1] Eye Clin Albury Wodonga, Albury, NSW, Australia
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2023年 / 51卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
下载
收藏
页码：1020 / 1020
页数：1
相关论文
共 50 条
  • [31] Three-Year Real World Outcomes of Aflibercept Treatment of Treatment-naive Patients with Neovascular Age-related Macular Degeneration
    Eleftheriadou, Maria
    Gemenetzi, Maria K.
    Sivaprasad, Sobha
    Hykin, Philip G.
    Hamilton, Robin
    Tufail, Adnan
    Patel, Praveen J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [32] Treatment of naive lesions in neovascular age-related macular degeneration with pegaptanib
    Quiram, Polly A.
    Hassan, Tarek S.
    Williams, George A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (07): : 851 - 856
  • [33] Consequences of Real-world Surveillance of Fellow Eyes in Neovascular Age-related Macular Degeneration
    Onwuka, Oluchukwu
    Saddemi, Jackson
    Akkan, F. Sema
    Lasalle, Claudia
    Ramsey, David J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [34] Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice
    Yiu, Glenn
    Gulati, Shilpa
    Higgins, Victoria
    Coak, Emily
    Mascia, Daniel
    Kim, Eunice
    Spicer, Galin
    Tabano, David
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 1679 - 1690
  • [35] Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study
    Souied, E.
    Clemens, A.
    Macfadden, W.
    ACTA OPHTHALMOLOGICA, 2017, 95
  • [36] Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
    Kikuchi, Yusuke
    Kawczynski, Michael G.
    Anegondi, Neha
    Neubert, Ales
    Dai, Jian
    Ferrara, Daniela
    Quezada-Ruiz, Carlos
    OPHTHALMOLOGY SCIENCE, 2024, 4 (02):
  • [37] Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)
    Giancipoli, Ermete
    Guglielmi, Antonella
    Bux, Anna Valeria
    Clima, Giulia Maria Emilia
    Pignatelli, Francesco
    Boscia, Francesco
    Viggiano, Pasquale
    Boscia, Giacomo
    Fortunato, Francesca
    Besozzi, Gianluca
    Niro, Alfredo
    Dore, Stefano
    Iaculli, Cristiana
    OPHTHALMOLOGY AND THERAPY, 2024, : 2163 - 2184
  • [38] One-year outcomes and safety assessment of faricimab in treatment-naive patients with neovascular age-related macular degeneration in Japan
    Mukai, Ryo
    Kataoka, Keiko
    Tanaka, Koji
    Miyara, Yasunori
    Maruko, Ichiro
    Nakayama, Makiko
    Watanabe, Yuto
    Yamamoto, Akiko
    Wakatsuki, Yu
    Onoe, Hajime
    Wakugawa, Sorako
    Terao, Nobuhiro
    Hasegawa, Taiji
    Kawai, Moeko
    Maruko, Ruka
    Itagaki, Kanako
    Honjo, Jyunichiro
    Okada, Annabelle A.
    Mori, Ryusaburo
    Koizumi, Hideki
    Iida, Tomohiro
    Sekiryu, Tetsuju
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [39] Outcomes at 1 Year with Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration: Real-World Results from the LUMINOUS Study
    Mitchell, Paul
    Macfadden, Wayne
    Lacey, Sue
    OPHTHALMOLOGICA, 2016, 236 : 1 - 1
  • [40] COST-EFFECTIVENESS OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CANADA
    Buhrer, C.
    Paulo, T.
    Diles, D.
    VALUE IN HEALTH, 2022, 25 (12) : S111 - S112
12345